Ultrarestrictive opioid prescription protocol for pain management after gynecologic and abdominal surgery J Mark, DM Argentieri, CA Gutierrez, K Morrell, K Eng, AD Hutson, ... JAMA network open 1 (8), e185452-e185452, 2018 | 122 | 2018 |
Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment KL Singel, TR Emmons, ANMNH Khan, PC Mayor, S Shen, JT Wong, ... JCI insight 4 (5), 2019 | 110 | 2019 |
On representing the prognostic value of continuous gene expression biomarkers with the restricted mean survival curve KH Eng, E Schiller, K Morrell Oncotarget 6 (34), 36308, 2015 | 83 | 2015 |
Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study JB Szender, T Emmons, S Belliotti, D Dickson, A Khan, K Morrell, ... Gynecologic oncology 146 (3), 491-497, 2017 | 75 | 2017 |
Mitochondrial DNA in the tumour microenvironment activates neutrophils and is associated with worse outcomes in patients with advanced epithelial ovarian cancer KL Singel, KS Grzankowski, ANMNH Khan, MJ Grimm, AC D’Auria, ... British journal of cancer 120 (2), 207-217, 2019 | 72 | 2019 |
Cancer stem cell and its niche in malignant progression of oral potentially malignant disorders S Surendran, G Siddappa, A Mohan, W Hicks Jr, V Jayaprakash, ... Oral oncology 75, 140-147, 2017 | 21 | 2017 |
Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancer KH Eng, K Morrell, K Starbuck, C Spring-Robinson, A Khan, D Cleason, ... Gynecologic oncology 146 (1), 52-57, 2017 | 21 | 2017 |
Prognostic impact of adjuvant chemotherapy treatment intensity for ovarian cancer KD Starbuck, JB Szender, WD Duncan, K Morrell, JL Etter, E Zsiros, ... PLoS One 13 (11), e0206913, 2018 | 12 | 2018 |
MICC: A tool for computing short distances in the curve complex P Glenn, WW Menasco, K Morrell, MJ Morse Journal of Symbolic Computation 78, 115-132, 2017 | 11 | 2017 |
Tackling the opioid crisis: Implementation of an ultra-restrictive opioid prescription protocol in patients undergoing major gynecologic surgery radically decreased dispensed … JE Mark, D Phoenix, CA Gutierrez, K Morrell, KH Eng, PC Mayor, ... Gynecologic Oncology 149, 5, 2018 | 7 | 2018 |
Metric In The Curve Complex. software P Glenn, WW Menasco, K Morrell, M Morse available at micc. github. io, 2014 | 6 | 2014 |
Implementation of a restrictive blood transfusion protocol in a gynecologic oncology service. J Mark, S Lynam, K Morrell, K Eng, K Starbuck, JB Szender, E Zsiros, ... Gynecology and reproductive endocrinology 3 (1), 1, 2019 | 4 | 2019 |
Proton pump inhibitor use during chemotherapy for platinum-resistant or platinum-refractory ovarian cancer improves overall survival K Starbuck, S Belliotti, K Morrell, JL Etter, K Kolesnikova, E Zsiros, ... Gynecologic Oncology 149, 68, 2018 | 4 | 2018 |
On representing the prognostic value of continuous gene expression biomarkers with the restricted mean survival curve. Oncotarget. 2015; 6 (34): 36308–18 KH Eng, E Schiller, K Morrell Epub 2015/10/22. https://doi. org/10.18632/oncotarget. 6121 PMID: 26486086, 0 | 4 | |
Expert Review of Cervical Cytology: Does it Affect Patient Care? J Mark, K Morrell, K Eng, A Alfiero, PJ Frederick Journal of lower genital tract disease 22 (2), 120-122, 2018 | 3 | 2018 |
TIGIT ligands CD155, CD112, and galectin-9 are associated with immune infiltration and increased overall survival in ovarian cancer K Starbuck, K Morrell, K Odunsi, E Zsiros, JB Szender, PJ Frederick, ... Gynecologic Oncology 149, 56, 2018 | 2 | 2018 |
How much is too much? Ending excessive opioid prescribing after major gynecologic oncology procedures JE Mark, D Phoenix, K Morrell, KH Eng, PC Mayor, K Starbuck, S Lynam, ... Gynecologic Oncology 154, 13-14, 2019 | 1 | 2019 |
Impact of ascites volume on clinical outcomes in epithelial ovarian cancer: A cohort study JB Szender, T Emmons, K Morrell, S Belliotti, D Dickson, A Khan, ... Gynecologic Oncology 145, 79, 2017 | 1 | 2017 |
Prognostic impact of adjuvant chemotherapy treatment delays for ovarian cancer: A cohort study K Starbuck, KH Eng, K Morrell, W Duncan, JL Etter, KB Moysich, K Odunsi, ... Gynecologic Oncology 149, 127-128, 2018 | | 2018 |
Operative time is a major modifiable risk factor impacting surgical outcomes in patients undergoing pelvic exenteration for gynecologic malignancy PC Mayor, K Fan, JL Etter, JB Szender, K Morrell, KH Eng, SN Akers, ... Gynecologic Oncology 149, 233, 2018 | | 2018 |